Results 201 to 210 of about 101,867 (267)

Monoamine oxidase inhibitor overdose

Annals of Emergency Medicine, 1984
Described is the clinical course of a 26-year-old woman who died following an overdose of the MAO inhibitor phenelzine. Signs and symptoms of toxicity were delayed in onset. Initial findings of excessive neuromuscular activity were followed by severe hyperthermia, coma, cardiovascular collapse, acute renal failure, hemolysis, rhabdomyolysis, and ...
C H, Linden, B H, Rumack, C, Strehlke
openaire   +2 more sources

Switching Monoamine Oxidase Inhibitors

Drug Intelligence & Clinical Pharmacy, 1985
Substituting one monoamine oxidase inhibitor for another is recommended only after a drug-free interval to avoid hypertensive emergencies. The evidence and mechanism firmly supporting this caution is lacking. We report a case where monoamine oxidase inhibitors were substituted without apparent adverse consequences.
B L, True, B, Alexander, B, Carter
openaire   +2 more sources

Monoamine oxidase inhibitors: a new generation.

Psychopharmacology bulletin
Monoamine oxidase inhibitors (MAOIs), which ushered in the modern era of psychopharmacology in the 1950s, have remained useful in the treatment of depression despite important safety concerns, such as acute hypertensive episodes brought on by ingestion ...
D. Robinson
semanticscholar   +1 more source

Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress.

Current Topics in Medicinal Chemistry, 2019
The development of xanthine oxidase and monoamine oxidase inhibitors led to important breakthroughs in the therapy of oxidative damage, hyperuricemia, gout, neurological, neuropsychiatric disorders and management of reperfusion injury.
Neelam Malik, Priyanka Dhiman, E. Sobarzo-Sánchez, A. Khatkar   +3 more
semanticscholar   +1 more source

Monoamine oxidase‐B inhibitors as potential neurotherapeutic agents: An overview and update

Medicinal research reviews (Print), 2019
Monoamine oxidase (MAO) inhibitors have made significant contributions and remain an indispensable approach of molecular and mechanistic diversity for the discovery of antineurodegenerative drugs.
R. Tripathi, S. R. Ayyannan
semanticscholar   +1 more source

Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status

Expert Opinion on Drug Metabolism & Toxicology, 2019
Introduction: Brain function depends considerably on the neurotransmission of biogenic monoamines. Their metabolism employs monoamine oxidase-B in neuronal and glial cells. Inhibition of monoamine oxidase-B elevates biogenic amine levels.
T. Müller, Jan-Dominique Möhr
semanticscholar   +1 more source

Monoamine Oxidase Inhibitors

Expert Opinion on Therapeutic Patents, 2002
Forty-nine monoamine oxidase inhibitor (MAOI)-related patents published between January 1998 and July 2002 are included in this review. They are classified and reviewed under three categories: (i) novel chemical entities, (ii) novel formulations, delivery systems and processing methods of known MAOIs and (iii) novel utilities and/or pharmaceutical ...
openaire   +2 more sources

Monoamine oxidase inhibitors

Abstract Monoamine oxidase inhibitors (MAOIs) are a separate class from other antidepressants, treating different forms of depression as well as other nervous system disorders such as panic disorder, social phobia, and depression with atypical features. They increase the availability of neurotransmitters such as norepinephrine, serotonin,
Neha Pawar, Timothy J. Wiegand
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Journal of Pharmaceutical Sciences, 1972
M Z, Hussain, M, Harinath
  +7 more sources

A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.

European journal of medicinal chemistry, 2020
Shoaib Manzoor, Nasimul Hoda
semanticscholar   +1 more source